| Health / Medical Topics |
MET Tyrosine Kinase Inhibitor PF-04217903
An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis. (NCI Thesaurus)
YOU MAY ALSO LIKE
A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma…
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor EMD 1214063 selectively binds to MET tyrosine kinase…
An inhibitor of the receptor tyrosine kinase Met (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds…
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth…
This gene plays a regulatory role in the modulation of cell-surface receptors and hepatocyte growth factor interactions.
A semisynthetic estrogen. Metabolized by the liver to ethynyl estradiol, mestranol serves as the estrogen component in several combination oral contraceptives. …
